AB Science Announces Significant Survival Data for Masitinib in ALS

This afternoon – this evening Paris-time – AB Science announced the publication of long-term follow-up data showing that lead compound, masitinib, extended survival in Amyotrophic Lateral Sclerosis (ALS) patients by 25 months compared to placebo when treatment was started early.